Black Swan Analysis Epiomic Epidemiology Forecast Report on Primary Carnitine Deficiency in 19 Major Markets
Systemic Primary Carnitine Deficiency CDSP is a rare autosomal recessive disorder caused by mutations in the SLC22A5 gene encoding organic cation transporter type 2 OCTN2 that transports carnitine across cell membranes. To date, more than 160 unique mutations in the SLC22A5 gene have been reported, and the type of mutation affects the severity of symptoms, with some carriers of less severe mutations being asymptomatic.
This report provides the current prevalent population for CDSP across 19 Major Markets USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina split by gender and 5year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a valueadded level of insight from the analysis team at Black Swan, several features of CDSP patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These subpopulations within the main disease are also included at a country level across the 10year forecast snapshot.
Main symptoms and comorbidities of CDSP include:
Hepatic and cardiac signs and symptoms
Anaemia
Proximal muscle weakness
Developmental delay
Respiratory distress
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most uptodate information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
Ability to quantify patient populations in global CDSP market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of CDSP and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding of the impact of specific comorbid conditions on the prevalent population of CDSP patients.
Identification of CDSP patient subpopulations that require treatment.
Better understanding of the specific markets that have the largest number of CDSP patients.
Original Article: EPIOMIC EPIDEMIOLOGY SERIES: PRIMARY CARNITINE DEFICIENCY FORECAST IN 19 MAJOR MARKETS 20182028 [Report Updated: 01012018] Prices from USD $5800